AbbVie

AL.com reports Howard Jacob is leaving the HudsonAlpha Institute for Biotechnology after three years there.

Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.

By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The team found that cancer-causing genes depend on the BTK gene, which they believe they can shut down with an existing drug.

The partners will use population genomics to discover and develop novel therapeutics and companion diagnostics for a range of chronic diseases.

Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.